ClinicalTrials.gg
CompletedNCT03029078FEDEXUpdated Jul 27, 2021

FEcal Transplant, a Hope to Eradicate Colonization of Patient Harboring eXtreme Drug Resistant Bacteria?

A Phase 4 interventional study of fecal microbiota transplant in Microbial Colonization, Bacterial Peritonitis and Faeces Smearing, sponsored by Centre d'Investigation Clinique et Technologique 805. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-07-27.

Sponsored by Centre d'Investigation Clinique et Technologique 805 · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 2 years 2 months after the study started (first participant enrolled Nov 2014, registered Jan 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies in Communicable Diseases with a site in France — 16 open to participants now, 16 under way, 2 of them phase 3. Communicable Diseases · France.

Planned enrollment
8th of 11
50 · median 75
Started
2014
the only one that year
Phase 4
2 of 42
none open now
Registered
6th of 42
by date
Lead sponsor
1 of 42
Centre d'Investigation Clinique et Technologique 805

Among the 42 studies in Communicable Diseases with a site in France, this one is the 8th largest by planned enrollment of the 11 interventional ones that give a count, is the only one that started in 2014, is one of 2 in phase 4, and was the 6th registered.

Communicable Diseases

628 studies on the registry are indexed under Communicable Diseases; 129 are open to participants now.

Browse Communicable Diseases studies →

Open to participants now

16 of the 42 studies in Communicable Diseases with a site in France are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 91 Communicable Diseases studies recruiting now, 49 (54%) set no upper age limit and 32 (35%) stop at 75 or younger; 35 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Communicable Diseases with a site in France, or all of them as a file.
02

Study summary

Our trial try to eradicate digestive tract colonization of patient harboring Extreme Drug Resistant (XDR) bacteria by performing a fecal transplantation.

Read the detailed description

Main objective:

Evaluate the eradication of the colonization of patient harboring XDR bacteria after a fecal transplantation from a healthy donor.

Secondary objectives:

English Evaluate the side effects of this procedure and tolerability. Evaluate the efficacy of the transplant if the patient is harboring glycopeptid resistant enteroccus (GRE) or carbapenem resistant enterobacteriae (CRE)

03

Conditions studied

  • Microbial Colonization
  • Bacterial Peritonitis
  • Faeces Smearing

Browse trials for

Keywords

  • XDR
  • fecal microbiota transplant
  • eradicate
  • colonization
  • CRE
  • GRE
  • bacteria
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient harboring a VRE or CRE bacteria
  • Colonization confirmed by our microbiology department, including at least 3 positives swabs in the last month

Exclusion criteria

Exclusion Criteria:

  • Pregnant woman or breastfeeding
  • including AIDS, over 60mg/day
  • ongoing antibiotic treatment at the day of inclusion
  • impossibility to obtain a signed consent form.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Fecal transplantation

    Patient will be transplanted with a healthy donor microbiota, free from XDR bacteria, in order to evaluate the impact on the digestive tract colonization Whole process of feces screening and reconstitution was under the responsibility of the pharmacists in charge of the study. Patient will benefit of a naso-duodenal tube in order to perform a bowel lavage prio to the fecal microbiota transplant. Patient will be monitored for 24h to rule out potential adverse events.

    Drug: fecal microbiota transplant

Interventions

  • DrugFecal microbiotaStudies of Fecal microbiotaFecal microbiota pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    We will perform a fecal microbiota transplant for patients harboring XDR bacteria in their digestive tract

    Also known as: FEDEX

06

What researchers measure

Primary outcomes

  1. Negativation of digestive tract colonization

    Negativation of the rectal swab performed, free from CRE or GRE

    Time frame: At one week, 2 weeks, one month up to 6 months

Secondary outcomes

  1. Metagenomics profile between donor and recipient depending on decolonization

    Study with a universal super donor in order to improve efficacy

    Time frame: At one week, 2 weeks, one month up to 3 months

07

Study locations

1 site
  • Hopital Raymond Poincaré
    Garches, 92380, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2014 to primary completion in Dec 2020, 73 months.

Of 13 phase 4 interventional studies under Communicable Diseases, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 65. This study's 73 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2017
First posted
Jan 24, 2017
StartActual
Nov 1, 2014
Primary completionActual
Dec 1, 2020
CompletionActual
Dec 1, 2020
Last update
Jul 27, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 27, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03029078
Lead sponsor
Centre d'Investigation Clinique et Technologique 805
Responsible party
Benjamin DAVIDO (M.D, M.S, Centre d'Investigation Clinique et Technologique 805) — Principal investigator
First posted
Jan 24, 2017
Start date
Nov 1, 2014
Primary completion
Dec 1, 2020
Completion
Dec 1, 2020
Last update
Jul 27, 2021

Study contacts

Benjamin Davido, MD, MS
principal investigator · Assistance Publique - Hôpitaux de Paris

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Fecal microbiota

Start the discussion